Walleye Capital
ADAP

Walleye Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

Walleye Capital’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-95,100
Closed -$952K – 812
2020
Q2 		$952K Buy
+95,100
New +$597K 0.21% 138

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Walleye Capital's ADAP Position: Q3 2020 in Review

Walleye Capital sold out of Adaptimmune Therapeutics (ADAP) in Q3 2020, closing a stake of 95,100 shares — an estimated $952K sold.

Walleye Capital first reported a position in ADAP in Q2 2020 and held it in 1 quarter. The position peaked at $952K in Q2 2020. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2020.

  • Walleye Capital reported no remaining Adaptimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Walleye Capital sold 95,100 Adaptimmune Therapeutics shares in Q3 2020, an estimated $952K.
  • Walleye Capital first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 1 quarter.
  • Walleye Capital's Adaptimmune Therapeutics position peaked at $952K in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2020.

Based on Walleye Capital's 13F filing for Q3 2020, filed 16 Nov 2020.